Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen

Journal of Clinical Oncology

Volumn 13, Issue 8, 1995, Pages 2117-2122

  Hesketh, Paul J ^a   Beck, Thomas ^b   Uhlenhopp, Mary ^b   Kris, Mark G ^b   Hainsworth, John D ^b   Harker, W Graydon ^b   Cohen, James R ^b   Lester, Eric ^b   Kessler, John F ^b   Griffen, Dan ^b   Rouse, Patti ^b  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; STREPTOZOCIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME; VOMITING;

EID: 0029154962     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.8.2117     Document Type: Article

References (18)

1. Hesketh PJ, Gandara DR: Serotonin antagonists: A new class of antiemetic agents. J Natl Cancer Inst 83:613-620, 1991
2. Del Favero A, Roila F, Tonato M: Reducing chemotherapy-induced nausea and vomiting. Drug Safety 9:410-428, 1993
3. Beck TM, Hesketh PJ, Madajewicz S, et al: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975, 1992
4. Ruff P, Paska W, Goedhals L, et al: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel-group study. Oncology 51:113-118, 1994
5. Smyth JF, Coleman RE, Nicolson M, et al: Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 303:1423-1426, 1991
6. Hesketh PJ, Harvey WH, Harker WG, et al: A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600, 1994
7. Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991
8. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - A randomised study. Eur J Cancer 29A:1669-1672, 1993
9. 3 receptor antagonists. Support Care Cancer 2:286-292, 1994
10. Kaizer L, Warr D, Hoskins P, et al: Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase II trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050-1057, 1994
11. Lindley CM, Bernard S, Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142-1149, 1989
12. Bodner M, White PF: Antiemetic efficacy of ondansetron after outpatient laparoscopy. Anesth Analg 73:250-254, 1991
13. Markham A, Sorkin EM: Ondansetron - An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45:931-952, 1993
14. Kris MG: Ondansetron: A specific serotonin antagonist for the prevention of chemotherapy-induced vomiting. Principles Practice Oncol PPO Updates 8:1-11, 1994
15. Weissbach L: Ondansetron. Lancet 338:753, 1991 (letter)
16. Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5, 1995
17. Johnson NE, Nash DB, Carpenter CE, et al: Ondansetron-Costs and resource utilisation in a US teaching hospital setting. Pharmacoeconomics 3:471-481, 1993
18. Petros WP, Peters WP: Cost implications of haematopoietic growth factors in the BMT setting. Bone Marrow Transplant 11:36-38, 1993 (suppl 2)